RxDoctor Payments Data

David Griffith, MD

Family Medicine · San Jose, CANPI 1790710903

Payments from drug & device makers

$537in general payments, 2019–2025

Across 10 payments — averaging $53.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$245
  • GSK$140
  • Teva Pharmaceuticals USA, Inc.$105
  • Pfizer$47

What the payments were for

  • Food & beverage$537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Globus Medical4$245
GSK3$140
Teva Pharmaceuticals USA, Inc.1$105
Pfizer2$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$537 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$212,284
Medicare patients
533
Services billed
2,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$82,766
OzempicSemaglutide52$57,230
JardianceEmpagliflozin24$32,365
FarxigaDapagliflozin Propanediol14$16,323
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,615
Levothyroxine Sodium337$4,900
Atorvastatin Calcium531$3,973
Incruse ElliptaUmeclidinium Bromide11$3,857
Tamsulosin Hcl231$3,744
Celecoxib59$3,000
Valsartan91$2,807
Gabapentin213$2,768
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide97$2,700
Rosuvastatin Calcium84$2,609
Losartan Potassium202$2,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$82,76674 claims
GSKTrelegy Ellipta, Incruse Ellipta$140$11,47123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →